FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease

Evstatiev, Rayko; Marteau, Philippe; Iqbal, Tariq; Халиф, И. Л.; Stein, Jürgen M.; Bokemeyer, Bernd; Chopey, Ivan V; Gutzwiller, F; Riopel, Lise; Gasché, Christoph

doi:10.1053/j.gastro.2011.06.005

Cited by 315 publications

(338 citation statements)

References 29 publications

Supporting

Mentioning

295

Contrasting

Unclassified

Order By: Relevance

“…21 Earlier starting of iron supplementation in these patients, seems to be the most important strategy. 22 David et al, Evstatiev et al and Iftikhar et al [23][24][25] proved that FCM was well tolerated and had better compliance than other iron preparations. The results of our study were consistent with the above mentioned trials.…”

Section: Discussionmentioning

confidence: 99%

Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

Mishra

Gandhi

Roy

et al. 2017

J Nepal Health Res Council

View full text Add to dashboard Cite

Background: Iron deficiency is a common nutritional deficiency amongst women of childbearing age. Peri-partum iron deficiency anaemia is associated with significant maternal, foetal and infant morbidity. Current options for treatment include oral iron, which can be ineffective and poorly tolerated, and red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a modern treatment option. The study was designed to assess the safety and efficacy of intravenous ferric carboxymaltose for correction of iron deficiency anaemia in pregnant women.Methods: A prospective study was conducted at Institute of Kidney Disease and Research Centre, Ahmedabad from January 2014 to December 2016. Antenatal women (108) with iron deficiency anaemia were the study subjects. Socio-demographic profile was recorded and anaemia was assessed based on recent haemoglobin reports. Iron deficiency was diagnosed on basis of serum ferritin value. Intravenous ferric carboxymaltose as per total correction dose (maximum 1500mg) was administered to all women; the improvement in haemoglobin levels were assessed after 3 weeks of total dose infusion. Results: Most of the women(n= 45, 41.7%), were in the age group of 27-30 years. Most of the women (n = 64, 59.3%) had moderate anaemia as per WHO guidelines. Mean haemoglobin levels significantly increased over a period of 3 weeks after Ferric carboxymaltose administrationand no serious life threatening adverse events were observed.Conclusions: Intravenous ferric carboxymaltose was safe and effective in pregnent women with iron deficiency anaemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

Mishra

Gandhi

Roy

et al. 2017

J Nepal Health Res Council

View full text Add to dashboard Cite

show abstract

“…Serum phosphate levels do not need to be checked or monitored, with the only possible exception of patients with IDA in the context of severe malnutrition, where baseline phosphate levels could be already reduced. On the other hand, FCM has been successfully and safely used in a number of clinical settings, including CHF [74,75], CKD [118], inflammatory bowel disease [119,120], heavy uterine bleeding [121], as well as during pregnancy in the second and third trimester [122,123].…”

Section: The Newer IV Iron Preparationsmentioning

confidence: 99%

Modern iron replacement therapy: clinical and pathophysiological insights

et al. 2017

View full text Add to dashboard Cite

Iron deficiency, with or without anemia, is extremely frequent worldwide, representing a major public health problem. Iron replacement therapy dates back to the seventeenth century, and has progressed relatively slowly until recently. Both oral and intravenous traditional iron formulations are known to be far from ideal, mainly because of tolerability and safety issues, respectively. At the beginning of this century, the discovery of hepcidin/ferroportin axis has represented a turning point in the knowledge of the pathophysiology of iron metabolism disorders, ushering a new era. In the meantime, advances in the pharmaceutical technologies are producing newer iron formulations aimed at minimizing the problems inherent with traditional approaches. The pharmacokinetic of oral and parenteral iron is substantially different, and diversities have become even clearer in light of the hepcidin master role in regulating systemic iron homeostasis. Here we review how iron therapy is changing because of such important advances in both pathophysiology and pharmacology.

show abstract

“…Regarding FCM safety, studies and reviews have not found any association with increased risk [17,19,[26][27][28][29][30]. A recent study in patients with heart failure and iron deficiency showed an improvement in functional capacity and even found an improvement in quality of life along with a trend towards fewer hospitalization rate for any cardiovascular cause or death in patients treated with FCM [30].…”

Section: Discussionmentioning

confidence: 99%

“…FCM has a higher price than other i.v. iron preparations, but the fact that a high dose can be administered in a single infusion may be a clear efficiency advantage: not only does it require fewer hospital visits and vein punctures [18,19] but also induces a better compliance allowing a quicker recovery of anemia, thus improving the preoperative status of the patient [19].…”

Section: Introductionmentioning

confidence: 99%

Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia

Calvet

Gené

ÀngelRuíz

et al. 2016

THC

View full text Add to dashboard Cite

FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease

Cited by 315 publications

References 29 publications

Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

Modern iron replacement therapy: clinical and pathophysiological insights

Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia

Contact Info

Product

Resources

About